Fox Chase Cancer Center Welcomes Lorenzo Galluzzi

Lorenzo New Hire
Fox Chase Cancer Center is pleased to announce the hiring of Lorenzo Galluzzi, PhD.

PHILADELPHIA (November 7, 2024) — Fox Chase Cancer Center is pleased to announce the hiring of Lorenzo Galluzzi, PhD, as an Associate Professor with tenure in the Cancer Signaling and Microenvironment Research Program.  

Prior to joining Fox Chase, Galluzzi was an Assistant Professor of cell biology in the Department of Radiation Oncology at the Weill Cornell Medical College in New York. His lab there focused on dissecting the links between adaptive stress responses of cancer cells and the activation of immune responses that target tumors during exposure to immunotherapy, chemotherapy, and radiation therapy.  

“We are enormously excited to welcome Dr. Galluzzi to the Fox Chase and Temple family and look forward to working with him to further strengthen an already robust research program,” said Edna “Eti” Cukierman, PhD, Co-Leader of the Cancer Signaling and Microenvironment Research Program and Marvin & Concetta Greenberg Chair in Pancreatic Cancer Research.

Galluzzi is an Assistant Professor Adjunct with the Department of Dermatology at the Yale School of Medicine and a faculty member with graduate schools at several Italian universities, including the Graduate School of Biomedical Sciences and Biotechnology at the University of Ferrara, the Graduate School of Pharmacological Sciences at the University of Padova, and the Graduate School of Network Oncology and Precision Medicine at the University of Rome.

He is also Associate Director of the European Academy for Tumor Immunology and a founding member of the European Research Institute for Integrated Cellular Pathology.

Galluzzi received his doctoral degree from Paris-Sud University in 2008 and completed his postdoctoral training at the Gustave Roussy Comprehensive Cancer Center in Paris.  

He has published over 500 scientific articles in peer-reviewed journals. Several outlets have named him a highly cited researcher worldwide from 2006 through 2023.

Galluzzi is Editor-in-Chief of the journals OncoImmunology, International Review of Cell and Molecular Biology, Methods in Cell Biology, and Molecular and Cellular Oncology. He is also a Consulting Editor for Pharmacological Research and an Associate Editor for Aging and Cell Death and Disease.

He is a member of the Spanish Group for Cancer Immune-Biotherapy, the Society for Immunotherapy of Cancer, the American Association for Cancer Research, the European Academy for Tumor Immunology, and the European Research Institute for Integrated Cellular Pathology. 

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427